CORDIS
EU research results

CORDIS

English EN
Hepatic and Cardiac Toxicity Systems modelling

Hepatic and Cardiac Toxicity Systems modelling

Objective

HeCaToS aims at developing integrative in silico tools for predicting human liver and heart toxicity. The objective is to develop an integrated modeling framework, by combining advances in computational chemistry and systems toxicology, for modelling toxic perturbations in liver and heart across multiple scales. This framework will include vertical integrations of representations from drug(metabolite)-target interactions, through macromolecules/proteins, to (sub-)cellular functionalities and organ physiologies, and even the human whole-body level. In view of the importance of mitochondrial deregulations and of immunological dysfunctions associated with hepatic and cardiac drug-induced injuries, focus will be on these particular Adverse Outcome Pathways. Models will be populated with data from innovative in vitro 3D liver and heart assays challenged with prototypical hepato- or cardiotoxicants; data will be generated by advanced molecular and functional analytical techniques retrieving information on key (sub-)cellular toxic evens. For validating perturbed AOPs in vitro in appropriate human investigations, case studies on patients with liver injuries or cardiomyopathies due to adverse drug effects, will be developed, and biopsies will be subjected to similar analyses. Existing ChEMBL and diXa data infrastructures will be advanced for data gathering, storing and integrated statistical analysis. Model performance in toxicity prediction will be assessed by comparing in silico predictions with experimental results across a multitude of read-out parameters, which in turn will suggest additional experiments for further validating predictions. HeCaToS, organized as a private-public partnership, will generate major socioeconomic impact because it will develop better chemical safety tests leading to safer drugs, but also industrial chemicals, and cosmetics, thereby improving patient and consumer health, and sustaining EU’s industrial competitiveness.

Coordinator

UNIVERSITEIT MAASTRICHT

Address

Minderbroedersberg 4-6
6200 Md Maastricht

Netherlands

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 2 673 569

Administrative Contact

René Reijnders (Mr.)

Participants (13)

Sort alphabetically

Sort by EU Contribution

Expand all

F. HOFFMANN-LA ROCHE AG

Switzerland

EU Contribution

€ 461 500

INSPHERO AG

Switzerland

EU Contribution

€ 262 500

FUNDACION PARA LA INVESTIGACION DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA

Spain

EU Contribution

€ 1 113 300

EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH

Switzerland

EU Contribution

€ 765 800

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

EU Contribution

€ 1 424 072

LUXCEL BIOSCIENCES LTD

Ireland

EU Contribution

€ 524 640

EUROPEAN MOLECULAR BIOLOGY LABORATORY

Germany

EU Contribution

€ 1 453 040

GENEDATA AG

Switzerland

EU Contribution

€ 659 432

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

Germany

EU Contribution

€ 650 262

KING'S COLLEGE LONDON

United Kingdom

EU Contribution

€ 337 500

RHEINISCH-WESTFAELISCHE TECHNISCHE HOCHSCHULE AACHEN

Germany

EU Contribution

€ 694 884

MicroDiscovery GmbH

Germany

EU Contribution

€ 497 500

OPTIBRIUM LIMITED

United Kingdom

EU Contribution

€ 482 000

Project information

Grant agreement ID: 602156

Status

Closed project

  • Start date

    1 October 2013

  • End date

    30 September 2018

Funded under:

FP7-HEALTH

  • Overall budget:

    € 15 990 000,20

  • EU contribution

    € 11 999 999

Coordinated by:

UNIVERSITEIT MAASTRICHT

Netherlands